Corient Private Wealth’s Crinetics Pharmaceuticals CRNX Stock Holding History

Corient Private Wealth’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$672K	Buy	+18,564	New	+$829K	﹤0.01%	1870

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Corient Private Wealth's CRNX Position: Q1 2026 in Review

Corient Private Wealth opened a new position in Crinetics Pharmaceuticals (CRNX) in Q1 2026: 18,564 shares worth $672K. The stake represents ﹤0.01% of the portfolio and ranks #1870 among its holdings.

243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

Corient Private Wealth held 18,564 shares of Crinetics Pharmaceuticals worth $672K as of Q1 2026.
Crinetics Pharmaceuticals was a new Corient Private Wealth position in Q1 2026.
Crinetics Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #1870 holding.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.